专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 陈乐奇的履历成为焦点：中国国籍，无境外永久居留权，1987年8月出生，现年38岁，硕士学历，注册 会计师。2009年本科毕业于复旦大学管理学院财务管理专业，2019年硕士研究生毕业于中欧国际工商学 院金融工商管理专业（FMBA）。 职业经历包括普华永道中天会计师事务所资深审计师、巴德医疗科技（上海）有限公司高级财务经理、 基立福医药科技（上海）有限公司财务总监。现任郑州莱士董事、GrifolsDiagnosticSolutionsInc．董 事、同路生物董事、同方莱士医药产业投资（广东）有限公司董事、广西莱士董事、上海莱士医药有限 公司财务负责人，并于2021年10月26日起担任上海莱士财务负责人。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，新浪财经《2024年度A股CFO数据报告》正式发布，全面梳理了上市公司财务总监（CFO）的薪 酬情况。数据显示，2024年A股上市公司CFO薪酬总额达42.70亿元，平均年薪为81.48万元。 报告进一步指出，医药生物行业（申万一级）CFO薪酬 ...

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has approved a share repurchase plan to enhance employee stock ownership and equity incentives, with a total repurchase amount ranging from RMB 250 million to RMB 500 million, at a maximum price of RMB 9.55 per share [1] Group 1: Share Repurchase Plan - The company plans to repurchase shares using self-owned or raised funds through centralized bidding in the secondary market [1] - The repurchase period is set for 12 months from the date of shareholder approval, with the possibility of early termination if certain conditions are met [1] Group 2: Progress of Share Repurchase - As of July 31, 2025, the company has repurchased a total of 65,321,952 shares, accounting for 0.98% of the total share capital, with a total transaction amount of approximately RMB 448.67 million [2] - The highest transaction price during the repurchase was RMB 7.09 per share, while the lowest was RMB 6.62 per share [2] Group 3: Compliance and Future Plans - The company's share repurchase activities comply with relevant regulations and guidelines set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [2][3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill information disclosure obligations as required by law [3]

Group 1 - The core point of the article is that Shanghai Laishi (002252) announced a share buyback program, having repurchased a total of 65,321,952 shares as of July 31, 2025, which represents 0.98% of the company's total share capital [1]

Group 1 - The company has responded to investor inquiries regarding its innovative drug projects, specifically mentioning the "SR604 injection" which is currently in Phase IIb clinical trials [2] - The SR604 injection is intended for subcutaneous administration to prevent and treat patients with Hemophilia A and B, as well as those with Factor VII deficiency [2]

Core Viewpoint - Shanghai Laishi (002252.SZ) has announced a share buyback program, indicating a strategic move to enhance shareholder value through the repurchase of its own shares [1] Summary by Relevant Categories Share Buyback Details - The company has repurchased a total of 65,321,952 shares, which represents 0.98% of its total share capital [1] - The highest transaction price during the buyback was 7.09 CNY per share, while the lowest was 6.62 CNY per share [1] - The total amount spent on the buyback reached 448,666,087.98 CNY, excluding transaction commissions and other fees [1]

上海莱士血液制品股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 1 月 13 日召开了第六 届董事会第七次（临时）会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有或自筹资金以集中竞价交易方式从二级市场回购公司股份，用 于实施员工持股计划或股权激励，拟回购股份的资金总额为不低于人民币 2.5 亿 元（含）且不超过人民币 5 亿元（含），拟回购股份价格不超过人民币 9.55 元/ 股（含），具体回购股份数量以回购股份方案实施完毕或回购实施期限届满时实 际回购情况为准。回购期限自股东大会审议通过本次回购股份方案之日起 12 个 月内，如果触及回购股份方案提及的相关条件时，回购期限提前届满。公司于 2025 年 2 月 14 日召开 2025 年第一次临时股东大会审议通过了上述股份回购方 案。具体内容详见公司分别于 2025 年 1 月 14 日、2025 年 2 月 15 日在《证券时 报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网（ ...

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries among company secretaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 make up 61%, while those over 50 account for 15%, and those aged 30-40 account for 18% [1] - In terms of education, 52% of company secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% have a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]